Juniper Biologics’ funding will help the expansion and innovation of Singapore’s pharmaceutical sector
SINGAPORE, Sept. 15, 2022 /PRNewswire/ — Juniper Biologics, a science-led speciality healthcare firm centered on commercialising novel therapies, at this time introduced the institution of its Global Headquarters in Singapore, from the place the Company will proceed the growth of its world operations. This announcement was supported by the Singapore Economic Development Board (EDB) who congratulated Juniper Biologics on the importance of this milestone. Juniper Biologics is backed by The Sylvan Group, an impartial non-public fairness funding agency centered on deep worth corporations with robust ESG-compliance.
The institution of its headquarters in Singapore is a part of Juniper Biologics’ dedication to Singapore and the broader area and can go in the direction of supporting the corporate’s plan to construct out a patient-centric presence all through key markets in the area and across the globe. Juniper Biologics proposes to hold out a full vary of actions for its fast-growing worldwide business for its portfolio of medicines in oncology and oncology supportive care, uncommon illnesses and gene remedy, with a objective of increasing entry of its pharmaceutical portfolio to sufferers throughout the rising markets. These actions embrace administration, coordination and management features of business actions for the group resembling medical affairs, regulatory affairs, business and business growth in addition to all finance and invoicing actions.
“Juniper Biologics’ decision to establish its global headquarters in Singapore affirms and reflects our position as a leading hub for pharmaceutical companies looking to drive and grow their businesses in the region. We welcome the addition of Juniper Biologics to our biomedical community and congratulate the company on this significant milestone.” mentioned Dr Beh Swan Gin, Chairman of the Economic Development Board.
“Singapore is an excellent hub for Juniper Biologics to base our global operations, giving us the combination of easy access with strong reach to support our goal of bringing the next generation of medicines to patients throughout the region and beyond,” mentioned Raman Singh, Chief Executive Officer of Juniper Biologics. “Singapore is fast-growing as a hub for pharmaceutical companies and this coupled with its strong infrastructure, make Singapore ideal to attract top-in-class talent which is essential for Juniper Biologics as we continue to develop in our role as a dynamic pharmaceutical company on the global stage.”
Since establishing its’s world operations in Singapore in 2020, Juniper Biologics has expanded its portfolio of medicines by way of the acquisition of novel therapies in oncology and oncology supportive care, uncommon illnesses and gene remedy.
About Juniper Biologics:
Backed by The Sylvan Group, Juniper Biologics is a science led healthcare firm centered on delivering novel therapies to enhance the well being and high quality of lifetime of sufferers, by constructing a rising presence in Oncology, Rare/Orphan Diseases and Gene Therapy. It was based on a imaginative and prescient to offer remedies for unmet medical wants centered on specialist remedy areas in which it could take advantage of distinction. Through daring and transformative science, Juniper Biologics is dedicated to creating prospects which have the potential to develop into the subsequent era of life-changing medicines for affected person communities in China, Japan, Asia, Australia, New Zealand, Middle East and Africa.
About The Sylvan Group:
The Sylvan Group is a number one non-public fairness funding agency based mostly out of Singapore and Seoul. The Sylvan Group’s focus is on investing in deep-value corporations with robust ESG-compliance throughout the Asia-Pacific area. The Sylvan group is supported by members of Hyundai & Rockefeller household and run by an skilled group of business professionals.
